| Literature DB >> 33254543 |
Jodi D Stookey1, Prasanna K R Allu2, Dorothee Chabas3, David Pearce4, Florian Lang5.
Abstract
To address urgent need for strategies to limit mortality from coronavirus disease 2019 (COVID-19), this review describes experimental, clinical and epidemiological evidence that suggests that chronic sub-optimal hydration in the weeks before infection might increase risk of COVID-19 mortality in multiple ways. Sub-optimal hydration is associated with key risk factors for COVID-19 mortality, including older age, male sex, race-ethnicity and chronic disease. Chronic hypertonicity, total body water deficit and/or hypovolemia cause multiple intracellular and/or physiologic adaptations that preferentially retain body water and favor positive total body water balance when challenged by infection. Via effects on serum/glucocorticoid-regulated kinase 1 (SGK1) signaling, aldosterone, tumor necrosis factor-alpha (TNF-alpha), vascular endothelial growth factor (VEGF), aquaporin 5 (AQP5) and/or Na+/K+-ATPase, chronic sub-optimal hydration in the weeks before exposure to COVID-19 may conceivably result in: greater abundance of angiotensin converting enzyme 2 (ACE2) receptors in the lung, which increases likelihood of COVID-19 infection, lung epithelial cells which are pre-set for exaggerated immune response, increased capacity for capillary leakage of fluid into the airway space, and/or reduced capacity for both passive and active transport of fluid out of the airways. The hypothesized hydration effects suggest hypotheses regarding strategies for COVID-19 risk reduction, such as public health recommendations to increase intake of drinking water, hydration screening alongside COVID-19 testing, and treatment tailored to the pre-infection hydration condition. Hydration may link risk factors and pathways in a unified mechanism for COVID-19 mortality. Attention to hydration holds potential to reduce COVID-19 mortality and disparities via at least 5 pathways simultaneously.Entities:
Keywords: ACE2 receptors; AQP5; COVID-19; Chronic hydration; Drinking water intervention; Hypertonicity; Mortality; SGK1; Saliva osmolality; VEGF
Mesh:
Substances:
Year: 2020 PMID: 33254543 PMCID: PMC7467030 DOI: 10.1016/j.mehy.2020.110237
Source DB: PubMed Journal: Med Hypotheses ISSN: 0306-9877 Impact factor: 1.538
Fig. 1Reproduced with permission from Rahmel et al [7]. Mean cumulative fluid balance with 95% CI for survivors and non-survivors of ARDS until ICU day 30.
| Biomarkers of chronic hypertonicity | Angiogenesis | Antioxidant | Passive transport | Active transport | Body water retention | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saliva Osmolality | Leukocyte SGK1 mRNA | Plasma VEGF | RBC GPX | Saliva AQP5 | RBC K:Na | Half-life of water in the body | Body weight | ||||||||
| Baseline | Change | Baseline | Change | Baseline | Change | Baseline | Change | Baseline | Change | Baseline | Change | Baseline | Change | Change | |
| mmol/kg | A.U. (2^-delta Ct) | ng/ml | nmol/min/mg Hb | ng/ml | Days | % | |||||||||
| 1 | 65 | −5 | 0.060 | −0.037 | 4670.8 | +1878 | 462.6 | −167.3 | 0.369 | +1.640 | 8.9 | −0.57 | 17.9 | −6.7 | +0.9 |
| 2 | 81 | +10 | 0.025 | −0.000 | 8807.3 | +767 | 596.5 | −31.1 | 0 | +0.158 | 9.7 | −0.70 | 15.3 | −4.7 | +3.0 |
| 3 | 106 | −19 | 0.080 | −0.018 | 3731.9 | +1213 | 401.8 | +84.0 | 0 | +1.82 | 9.3 | −1.50 | 15.0 | −1.6 | +2.7 |
| 4 | 122 | −45 | 0.067 | −0.032 | 3175.7 | +2823 | 455.1 | +163.7 | 0.153 | +0.084 | 11.1 | −1.79 | 11.4 | −1.8 | +2.0 |
| 5 | 153 | −36 | 0.122 | −0.064 | 4213.4 | +2257 | 318.4 | +207.0 | 0.464 | −0.352 | 8.5 | −1.71 | 11.6 | −2.5 | +0.6 |